Montelucaste Apilif (Montelukast)

Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotriene D4 from triggering bronchoconstriction and inflammation. By inhibiting this pathway, it reduces airway narrowing, mucus production, and allergic symptoms.

The specific dose of Montelucaste Apilif is determined by the prescribing clinician based on the patient’s age, condition severity, and response to therapy. Only a qualified healthcare professional should set the dosing regimen.

Safety data for montelukast in pregnancy and lactation are limited. The prescriber should weigh potential benefits against risks and consider alternative therapies if appropriate. Women who are pregnant or nursing should discuss use with their healthcare provider.

To request Montelucaste Apilif, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with allergic components or exercise‑induced symptoms, but it does not replace rescue bronchodilators for acute attacks.

Montelucaste Apilif should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain stability and potency.

The medication is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole; do not crush, chew, or split unless specifically instructed.

Serious risks include neuropsychiatric events such as depression, suicidal thoughts, and mood changes, as well as severe allergic reactions like anaphylaxis or Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelucaste Apilif is contraindicated in individuals with known hypersensitivity to montelukast or any of the tablet’s excipients. It should also be used with caution in patients with severe liver impairment or a history of neuropsychiatric disorders.